Transkaryotic Therapies (TKTX) | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Transkaryotic Therapies (TKTX)

An SI Board Since April 2000

Posts	SubjectMarks	Bans	Symbol
12	4	0	TKTX

Emcee: paradigm7241	Type: Unmoderated

Introduction Market Data Compact

Transkaryotic Therapies is an innovative biotech company whose niche technology is the production of commercial quantities of endogenous human proteins such as Epo by inserting constitutively active promoter regions upstream to the target gene in human cell lines. This method avoids the use of transgenes and non human cell lines which do not glycosylate proteins in precisely the native pattern. Many companies producing recombinant human proteins are threatened by TKTX's technology worried that their patents will not cover this novel method of protein production.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
12	Two Firms Say Fabry Drugs Succeed in Trials Last updat	sim1	-	10/6/2000
11	Surprised no move in prices - didn't the Fat Lady just sing? Here's th	Jesse Schulman	-	4/27/2000
10	update..... Wednesday April 26, 2:17 pm Eastern Time Company Press Release F	scaram(o)uche	-	4/26/2000
9	"Correct me if I'm wrong" OK. You're wrong. Your pet the	Jesse Schulman	-	4/22/2000
8	"Non-human DNA sequences which control transcription" seems to me to	paradigm7241	-	4/21/2000
7	AMGEN'S EPO PATENT ABSTRACT Production of erthropoietin Abstract Disclos	paradigm7241	-	4/21/2000
6	The post by sjhurst at Fool.com is an intellegent opinion on the case although	paradigm7241	-	4/21/2000
5	Don't fall for TKTX as Robin Hood. More like Aventis' stalking horse i	Jesse Schulman	-	4/21/2000
4	I believe that Amgen's method is substantially quite different from that of	david james	-	4/21/2000
3	Paradigm: Your view is shared among most of those who (1) know the sector, and	scaram(o)uche	-	4/21/2000
2	THE DISPUTE Amgen is sueing TKTX for patent infringement with regard to the p	paradigm7241	-	4/21/2000
1	OVERVIEW TKTX's technology focuses on promoter enhanced gene expression/en	paradigm7241	-	4/21/2000

Go to reply# or date (mm/dd/yy):